High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
Clinical trial NCT01183416 · COMPLETED
Trial details
- NCT number
- NCT01183416
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-08-01
- Primary completion
- 2018-10-31
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.